CYTARABINE
- Strength
- 20 mg/mL
- Form
- Injection, Solution
- Class
- Nucleoside Metabolic Inhibitor
Hospira, Inc.
Listed by Gland Pharma Limited
| Dosage form | Injection, Solution |
|---|---|
| Route | Intrathecal, Intravenous, Subcutaneous |
| Drug class | Nucleoside Metabolic Inhibitor |
| Approval route | ANDA — approved generic |
| NDC code | 68083-337 |
| FDA application | ANDA211938 |
| RxNorm concept | 249364 |
| Package sizes listed | 1 |
| Marketed since | December 2019 |
Same active ingredient, different manufacturer, strength or form. Products matching on both ingredient and strength are usually interchangeable — but confirm before switching, especially with modified-release forms.
Hospira, Inc.
Meitheal Pharmaceuticals Inc.
Sagent Pharmaceuticals
Hospira, Inc.
Gland Pharma Limited
Meitheal Pharmaceuticals Inc.
Fresenius Kabi USA, LLC
Meitheal Pharmaceuticals Inc.
Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.
Please don't share card details in chat.